The Traderszone Network

Published in TZ Latest News 11 July, 2017 by The TZ Newswire Staff

Here’s Why AVEO Oncology Fell as Much as 12.7% Today

Shares of biopharma AVEO Oncology (NASDAQ: AVEO) fell as much as 12.7% today following continued momentum trading. Things haven’t quite been the same for the stock since June 23. That’s when it announced data from a pivotal phase 3 trial for its lead drug candidate tivozanib, which was evaluated as a treatment for renal cell carcinoma.

read more